Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 10, 2019 (7 years ago)

Robafen DM

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Robafen DM, Generic for Robitussin DM, In each teaspoonful (5mL): Dextromethorphan HBr, USP 10mg,/Guaifenesin, USP 100mg, 118mL (4oz) bottle, Manufactured for Preferred Pharmaceuticals, Inc., Anaheim, CA 92807 by Major Pharmaceuticals, Livonia, MI 48152, NDC 68788-0841-01

Affected NDC 68788-0841-01

Compare with the code on your package — it is the most precise check available.

Drug: Guaifenesin

Recalling firm
Preferred Pharmaceuticals, Inc
NDC code
68788-0841-01
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1410-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Guaifenesin recalls

See all
Class III · Low risk

Kids' Cough and Chest Congestion

Crystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.

Ongoing Failed specification Denison Pharmaceuticals, LLC D-0034-2025

Other recalls by Preferred Pharmaceuticals, Inc

All 2019 recalls
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026
Class II · Moderate risk

Ibuprofen Tablets

Failed Impurities/Degradation Specifications - at 18-month Stability testing

Ongoing Impurity / degradation Preferred Pharmaceuticals, Inc. NDC 68788-9110-03 D-0647-2024